Digi-Prex.com

Digi-Prex is an innovative pharmacy service offering subscription-based medication deliveries directly to customers, enhancing accessibility and affordability in pharmaceutical care through seamless technology integration. Founded in 2019, Digi-Prex operates as a direct-to-consumer pharmacy service in Hyderabad, India, focusing on delivering medication to customers' doorsteps. The company raised USD 5. 50 mn in a Seed funding round on September 20, 2019, with investors including Khosla Ventures, Quiet Capital, SV Angel, Vedanta Capital, and Y Combinator.

Samarth Sindhi, the founder, has a history in entrepreneurship, contributing to the company's strategic direction and growth. Digi-Prex primarily offers a subscription-based pharmacy service that delivers monthly supplies of medication directly to customers' doorsteps without additional costs. The service aims to provide a seamless experience by allowing users to upload prescriptions via WhatsApp, confirming orders easily, and benefiting from automatic monthly reordering. This personalized pharmacy approach enhances medication accessibility and offers significant savings, with prices up to 15% lower than traditional pharmacies.

The target customer base includes individuals requiring regular medications, busy professionals, and families seeking convenience and reliability in their pharmaceutical needs, specifically in urban markets across India. In 2023, Digi-Prex generated revenues amounting to USD 19,342,983. 60 with an EBITDA of USD 17,350. 80, primarily from its subscription models for pharmacy services which involve customers sharing prescriptions and receiving medications directly at home.

The company also enhances customer engagement through a referral program that incentivizes existing customers to bring in new clients, fostering loyalty and promoting consistent usage of its services. Digi-Prex aims to leverage its recent Seed funding of USD 5. 50 mn raised in September 2019 to expand its service offerings and market presence. Plans include the development of new pharmacy-related products, though specific details and release dates are yet to be disclosed.

The company is also targeting expansion into additional urban markets across India to meet growing demand for efficient healthcare solutions, with strategic initiatives supported by investor resources.